T cells could be the key in developing an effective COVID-19 vaccine
Many have embraced and the possibility of immunity to COVID-19 as the key to reopening society and the economy. Serology testing — also known as antibody testing — can indicate whether someone is producing an immune response to the virus.
But we still do not know whether the presence of antibodies in recovered patients holds promise for long-lasting immunity. Insight from immunological studies on recovered SARS patients infected in 2003 showed that antibody levels wane after just . A different immune response caused by T cells provides long term protection, even .
Based on this data, it is likely that T cell responses play a substantial role in developing protective immunity against SARS-CoV-2, the virus that causes COVID-19. There are of T cells: helper and killer T cells. When they recognize a virus, helper T cells signal to activate other types of immune cells, while killer T cells release molecules that destroy the virus.
In a , researchers at the La Jolla Institute for Immunology identified viral protein pieces in SARS-CoV-2 that are already known to induce T cell immune responses. They then exposed the immune cells from 10 recovered COVID-19 patients to these protein pieces and measured the T cell immune responses.
All of the patients had helper T cells that recognized the main SARS-CoV-2 spike protein, and about 70% of them also had killer T cells that recognized the spike and membrane proteins. The main target of the is the antibody response to the spike protein, but this new understanding of the T cell response could provide new and potentially better targets.
The mission to make a vaccine against COVID-19 is possibly the most urgent public health problem in the world today. The encouraging results in both the similarities in immune response to SARS and SARS-CoV-2 and the identification of strong T cell responses in recovered COVID-19 patients promote further research in designing vaccines to induce T cell responses.
This story originally appeared on , an editorial partner site that publishes science stories by scientists. to get even more science sent straight to you.

Enjoy reading 91ÑÇÉ«´«Ã½ Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from 91ÑÇÉ«´«Ã½ Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Meet Robert Helsley
The Journal of Lipid Research junior associate editor studies chronic liver disease and was the first in his family to attend college.

From the Journals: MCP
Protein acetylation helps plants adapt to light. Mapping protein locations in 3D tissues. Demystifying the glycan–protein interactome. Read about these recent papers.

Exploring life’s blueprint: Gene expression in development and evolution
Meet Julia Zeitlinger and David Arnosti — two co-chairs of the 91ÑÇÉ«´«Ã½â€™s 2025 meeting on gene expression, to be held June 26-29, in Kansas City, Missouri.

From the journals: JLR
Protein analysis of dopaminergic neurons. Predicting immunotherapy responses in lung cancer. ZASP: An efficient proteomics sample prep method. Read about papers on these topics recently published in Molecular & Cellular Proteomics.

New mass spectrometry assay speeds up UTI diagnosis
Scientists in Quebec use liquid chromatography–mass spectrometry to reduce the time needed to test for bacteria in urine from days to minutes — and with smaller samples.

From the journals: MCP
Protein analysis of dopaminergic neurons. Predicting immunotherapy responses in lung cancer. ZASP: An efficient proteomics sample prep method. Read about papers on these topics recently published in Molecular & Cellular Proteomics.